利妥昔单抗联合ESHAP方案治疗复发非霍奇金淋巴瘤临床观察

目的 观察利妥昔单抗(Rituximab)联合ESHAP方案(依托泊苷、甲基强的松龙、顺铂、阿糖胞苷)治疗复发的CD20阳性B细胞性非霍奇金淋巴瘤(non-Hodgkinslymphoma,NHL)的临床疗效及安全性.方法 回顾性分析我院以利妥昔单抗联合ESHAP方案及单用ESHAP方案治疗复发的CD20阳性B细胞性非霍奇金淋巴瘤的临床资料.32例复发的CD20阳性的B细胞非霍奇金淋巴瘤患者,随机分为利妥昔单抗联合ESHAP方案组(治疗组)及单用ESHAP方案组(对照组),每21 d为1个周期,重复治疗.全部32例患者完成4个周期化疗后进行疗效评价.结果 治疗组完全缓解率(CR)为37.5%,总有效率为87.5%;对照组分别为25%、56.3%,两组有效率有显著性差异(P<0.05).两组患者不良反应主要为轻中度骨髓抑制、脱发和消化道反应.不良反应发生率相近(P>0.05),均可耐受.治疗组1例(6.25%)出现利妥昔单抗输注相关的不良反应,经对症处理后好转.结论 利妥昔单抗联合ESHAP方案治疗复发的CD20阳性B细胞性非霍奇金淋巴瘤安全有效,患者耐受良好,应推荐使用.

Clinical observation of rituximab and ESHAP regiment in the treatment of relapsed non-Hodgkin Lymphoma

Objective To analyze the efficacy and safety of rituximab and ESHAP regiment(etoposide,methylprednisolone,cisplatin,cytosine arabinoside) in the treatment of relapsed CD-positived B-cell non-Hodgkin’s lymphoma(NHL).Methods 32 cases of relapsed CD-positived B-cell NHL were randomly divided into treatment group(rituximab and ESHAP regiment) and control group(ESHAP only).Chemotherapy of all patients were repeated every 21 days for 4 cycles.Results The complete remission rate and efficacy rate were 37.5%,97.5% in treatment group and 25%,56.3% in control group,respectively.But both group had similar adverse effect rates,including mild and moderate inhibition of bone marrow,hair loss and gastrointestinal disorders.Rituximab-related adverse was occurred in 1 case,cured after treatment.Conclusion The treatment of relapsed CD-positived B-cell NHL with rituximab and ESHAP regiment was safe and effective and good tolerance.It should be recommended.